LNTH INVESTOR ALERT: Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Core Viewpoint - The Lantheus Holdings, Inc. class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly concerning its key product, Pylarify, which is used in prostate cancer diagnosis and treatment [1][3]. Group 1: Allegations and Financial Impact - The lawsuit claims that Lantheus created a false impression of having reliable information about its projected revenue and growth while downplaying risks from competition and market dynamics [3]. - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales and reduced its full-year growth projections from low-single-digit to mid-single-digit growth to flat-to-low single-digit growth, resulting in a stock price drop of over 23% [4]. - On August 6, 2025, Lantheus announced further disappointing results, with Pylarify sales down 8.3% year-over-year, leading to a nearly 29% decline in stock price after slashing fiscal year 2025 growth projections [5]. Group 2: Legal Process and Representation - Investors who purchased Lantheus securities during the class period (February 26, 2025, to August 5, 2025) can seek appointment as lead plaintiff in the class action lawsuit, which allows them to act on behalf of other class members [6]. - The lead plaintiff can choose a law firm to represent the class, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [6]. Group 3: Company Overview - Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products for heart, cancer, and other diseases, with Pylarify being a key product in its portfolio [2].